Clostridium Difficile News and Research

RSS

Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

PHT Corporation announced that Sanofi Pasteur is using PHT’s LogPad® System and StudyWorksTM online portal for a Phase II trial to develop a vaccine against the Clostridium difficile bacterium.

17 Dec 2009

Cubist Pharmaceuticals acquires Calixa Therapeutics

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company has completed its previously announced acquisition of Calixa Therapeutics Inc.,

17 Dec 2009

New licensing agreement to develop and commercialize prophylactic vaccine against MRSA signed

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that it has entered into an exclusive, world-wide licensing agreement with Syntiron to develop and commercialize its prophylactic vaccine against Staphylococcus, including Methicillin-Resistant Staphylococcus aureus or MRSA.

17 Dec 2009

Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals

Nanotherapeutics, Inc., a privately held biopharmaceutical company, announced that it has acquired in bankruptcy proceedings two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 from EPIX Pharmaceuticals, Inc.

16 Dec 2009

Optiquant BKV Quantification Panel for MSSA DNA testing procedures

AcroMetrix, a leading provider of quality control standards for clinical diagnostic laboratories, announced today the launch of the first standardized quality control for MSSA molecular testing.

15 Dec 2009

Trial date set for patent litigation in the U.S. District Court for the District of Delaware

Cubist Pharmaceuticals, Inc. today announced that a trial date has been set for patent litigation in the U.S. District Court for the District of Delaware against Teva Parenteral Medicines, Inc. (TPM), Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. alleging infringement of Cubist’s US Patent Nos. 6,468,967 and 6,852,689, which expire on September 24, 2019, and US Patent No. RE39,071, which expires on June 15, 2016.

14 Dec 2009

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Cubist Pharmaceuticals, Inc. a leading acute care therapeutics company, announced today the signing of a definitive agreement under which Cubist has agreed to acquire privately held Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.

14 Dec 2009

Enrollment closed early in Cubist Pharmaceuticals' ecallantide Phase 2 program

Cubist Pharmaceuticals, Inc. today announced the early closing of enrollment in its ecallantide Phase 2 program. Ecallantide, in development as therapy to reduce bleeding in on-pump cardiac surgery, is now known as CB-500,929. After a regularly scheduled review meeting, the Data Safety Monitoring Board (DSMB) contacted the company to recommend a temporary suspension in enrollment in one of the CB-500,929 trials, CONSERV-2.

3 Dec 2009

Medical Nutrition launches Diff-Stat pre- and probiotic supplement to prevent the onset of AAD and C-diff

Medical Nutrition USA, Inc., a developer and distributor of uniquely engineered, nutrition-medicine products, announced the introduction of Diff-Stat™, a new supplement containing pre- and probiotics to help restore and maintain beneficial bacteria that prevent the onset of antibiotic-associated diarrhea (AAD) and clostridium difficile (C-diff).

24 Nov 2009

BD acquires HandyLab for $275 million

BD today announced the completion of its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms.

From BD (Becton, Dickinson and Company) 20 Nov 2009

AvidBiotics granted U.S. and European patents concerning its DGR technology platform

AvidBiotics Corp. announced the issuance of foundational patents encompassing a completely novel mechanism for generating massive diversity within precisely targeted sites of protein-encoding DNA sequences. The technology platform is referred to as Diversity Generating Retroelements (DGR) and patents were issued in both the United States (#7,585,957) and in Europe (#1,173,995). UCLA and AvidBiotics Corp are co-assignees of the patents, and AvidBiotics holds exclusive, worldwide rights to the patents from UCLA.

13 Nov 2009

Optimer Pharmaceuticals presents additional data from Phase 3 fidaxomicin study

Optimer Pharmaceuticals, Inc. today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia, PA.

2 Nov 2009

Unexpected consequences emerge in patients who are prescribed PPI medications for reflux diseases

Despite being highly effective and beneficial for many patients, unexpected consequences are emerging in patients who are prescribed proton pump inhibitors (PPIs) for reflux diseases. Physicians are warned to monitor these effects and prescribe these medications carefully, according to a new commentary published in the November 2009 issue of Otolaryngology - Head and Neck Surgery.

2 Nov 2009

Gen-Probe receives FDA emergency use authorization for its Prodesse ProFlu-ST test

Gen-Probe Incorporated today announced that the US Food and Drug Administration (FDA) has granted an EUA (emergency use authorization) for its test, the Prodesse ProFlu-ST(TM), to be used in CLIA high complexity laboratories for the diagnosis of 2009 H1N1 influenza virus infection, aided by an algorithm that relies on seasonal influenza A/H1 virus and seasonal influenza A/H3 virus results, from a single sample in individuals who are diagnosed with influenza A by currently available FDA-cleared or authorized devices.

29 Oct 2009

NIH awards Excelimmune grant to develop treatment for Clostridium difficile infection

Excelimmune, Inc. (www.excelimmune.com) announced today that the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant to support research aimed at developing new treatments for Clostridium difficile (C. difficile) infection, employing Excelimmune’s expertise in developing novel antibody therapies for human disease.

28 Oct 2009

HHS funds projects to combat health care-associated infections

HHS Secretary Kathleen Sebelius today announced the award of $17 million to fund projects to fight costly and dangerous health care-associated infections, or HAIs.

28 Oct 2009

Stomach infection on the rise in outpatient settings; symptoms can range from diarrhea to life-threatening inflammation

Mayo Clinic researchers have found that a sometimes deadly stomach bug, Clostridium difficile, (http://www.mayoclinic.org/c-difficile/) is on the rise in outpatient settings.

27 Oct 2009

BD to acquire HandyLab

BD (Becton, Dickinson and Company)announced today that it signed a definitive agreement to acquire HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms. The acquisition is subject to regulatory approvals and is expected to close during the first quarter of fiscal year 2010. The financial terms of the agreement were not disclosed.

From BD (Becton, Dickinson and Company) 24 Oct 2009

HHS funds $17M for fight against costly and dangerous health care-associated infections

HHS Secretary Kathleen Sebelius today announced the award of $17 million to fund projects to fight costly and dangerous health care-associated infections, or HAIs.

24 Oct 2009

Gen-Probe acquires Prodesse

Gen-Probe announced today that the Company has completed its acquisition of Prodesse, Inc., a leader in molecular testing for influenza and other infectious diseases, for approximately $60 million in cash.

23 Oct 2009

Clostridium Difficile News and Research

Further Reading

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

Cubist Pharmaceuticals acquires Calixa Therapeutics

New licensing agreement to develop and commercialize prophylactic vaccine against MRSA signed

Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals

Optiquant BKV Quantification Panel for MSSA DNA testing procedures

Trial date set for patent litigation in the U.S. District Court for the District of Delaware

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Enrollment closed early in Cubist Pharmaceuticals' ecallantide Phase 2 program

Medical Nutrition launches Diff-Stat pre- and probiotic supplement to prevent the onset of AAD and C-diff

BD acquires HandyLab for $275 million

AvidBiotics granted U.S. and European patents concerning its DGR technology platform

Optimer Pharmaceuticals presents additional data from Phase 3 fidaxomicin study

Unexpected consequences emerge in patients who are prescribed PPI medications for reflux diseases

Gen-Probe receives FDA emergency use authorization for its Prodesse ProFlu-ST test

NIH awards Excelimmune grant to develop treatment for Clostridium difficile infection

HHS funds projects to combat health care-associated infections

Stomach infection on the rise in outpatient settings; symptoms can range from diarrhea to life-threatening inflammation

BD to acquire HandyLab

HHS funds $17M for fight against costly and dangerous health care-associated infections

Gen-Probe acquires Prodesse

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News